Research graph
References from Identification of key genes and metabolites in thyroid eye disease through integrated transcriptomic and metabolomic analysis. Local targets link to admitted publications; unresolved targets remain external evidence.
Management of thyroid eye disease: A consensus statement by the American Thyroid Association and the European Thyroid Association
10.1089/thy.2022.0251 · 2022 · External reference
Investigating factors influencing quality of life in thyroid eye disease: Insight from machine learning approaches
10.1530/etj-24-0292 · 2025 · External reference
Thyroid eye disease (Graves' orbitopathy): Clinical presentation, epidemiology, pathogenesis, and management
10.1016/s2213-8587(25)00066-x · 2025 · External reference
Predictive score for the development or progression of Graves' orbitopathy in patients with newly diagnosed Graves' hyperthyroidism
10.1530/eje-18-0039 · 2018 · External reference
Teprotumumab for patients with active thyroid eye disease: A pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials
10.1016/s2213-8587(21)00056-5 · 2021 · External reference
The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy
10.1530/eje-21-0479 · 2021 · External reference
Thyroid eye disease: Current and potential medical management
10.1007/s10792-019-01258-7 · 2020 · External reference
Epidemiology, natural history, risk factors, and prevention of Graves' orbitopathy
10.3389/fendo.2020.615993 · 2020 · External reference
A multicenter, single-blind, case-control, immunohistochemical study of orbital tissue in thyroid eye disease
10.1089/thy.2022.0173 · 2022 · External reference
Current perspectives on the role of orbital fibroblasts in the pathogenesis of Graves' ophthalmopathy
10.1016/j.exer.2015.02.007 · 2016 · External reference
SOX9 induces orbital fibroblast activation in thyroid eye disease via MAPK/ERK1/2 pathway
10.1167/iovs.65.2.25 · 2024 · External reference
Fibrosis in dysthyroid eye disease
10.1038/s41433-019-0731-5 · 2020 · External reference
Multi-omics approaches to discover biomarkers of thyroid eye disease: A systematic review
10.7150/ijbs.103977 · 2024 · External reference
A pathway analysis based on genome-wide DNA methylation of Chinese patients with Graves' orbitopathy
10.1155/2019/9565794 · 2019 · External reference
Hypo vs. hyperthyroid eye disease: Is there any difference
10.1186/s12886-023-02806-7 · 2023 · External reference
Orbital clinicopathological differences in thyroid eye disease: An analysis of cytokines with histopathological and clinical correlation
10.1167/iovs.66.3.33 · 2025 · External reference
Socioeconomic disparities in the presentation and treatment of Graves' disease and thyroid eye disease
10.1080/08820538.2016.1185322 · 2016 · External reference
Hyperthyroid vs hypothyroid eye disease: The same severity and activity
10.1038/eye.2011.186 · 2011 · External reference
Dynamic transition of Tregs to cytotoxic phenotype amid systemic inflammation in Graves' ophthalmopathy
10.1172/jci.insight.181488 · 2024 · External reference
Teprotumumab for the treatment of thyroid eye disease
10.1210/endrev/bnae018 · 2024 · External reference
Phenotypes of thyroid eye disease
10.1097/iop.0000000000001147 · 2018 · External reference
Transparency in the reporting of artificial intelligence – The TITAN guideline
10.70389/pjs.100082 · 2025 · External reference
Parallel gene expression changes in sarcoidosis involving the lacrimal gland, orbital tissue, or blood
10.1001/jamaophthalmol.2015.0726 · 2015 · External reference
Fibrosis, gene expression and orbital inflammatory disease
10.1136/bjophthalmol-2015-306614 · 2015 · External reference
Next-generation sequencing: ForenSeq™ DNA signature prep kit with the Illumina MiSeq FGx
10.1007/978-1-0716-3295-6_24 · 2023 · External reference
featureCounts: An efficient general purpose program for assigning sequence reads to genomic features
10.1093/bioinformatics/btt656 · 2014 · External reference
Harmonizing lipidomics: NIST interlaboratory comparison exercise for lipidomics using SRM 1950-metabolites in frozen human plasma
10.1194/jlr.m079012 · 2017 · External reference
Development of a high coverage pseudotargeted lipidomics method based on ultra-high performance liquid chromatography-mass spectrometry
10.1021/acs.analchem.8b01331 · 2018 · External reference
metaX: A flexible and comprehensive software for processing metabolomics data
10.1186/s12859-017-1579-y · 2017 · External reference
KEGG mapper for inferring cellular functions from protein sequences
10.1002/pro.3711 · 2020 · External reference
KEGG for taxonomy-based analysis of pathways and genomes
10.1093/nar/gkac963 · 2023 · External reference
clusterProfiler: An R package for comparing biological themes among gene clusters
10.1089/omi.2011.0118 · 2012 · External reference
WGCNA: An R package for weighted correlation network analysis
10.1186/1471-2105-9-559 · 2008 · External reference
Metagenomic biomarker discovery and explanation
10.1186/gb-2011-12-6-r60 · 2011 · External reference
Machine learning-derived diagnostic model of epithelial ovarian cancer based on gut microbiome signatures
10.1186/s12967-025-06339-z · 2025 · External reference
Effect of overconditioning on the hepatic global gene expression pattern of dairy cows at the end of pregnancy
10.3168/jds.2020-19302 · 2021 · External reference
Novel therapeutic targets for major depressive disorder related to oxidative stress identified by integrative multi-omics and multi-trait study
10.1038/s41398-024-03126-0 · 2024 · External reference
Support vector machine algorithms in the search of KIR gene associations with disease
10.1016/j.compbiomed.2013.09.027 · 2013 · External reference
An R package for ensemble learning stacking
10.1093/bioadv/vbad139 · 2023 · External reference
Robust enumeration of cell subsets from tissue expression profiles
10.1038/nmeth.3337 · 2015 · External reference
Investigating immune cell infiltration and gene expression features in pterygium pathogenesis
10.1038/s41598-025-98042-8 · 2025 · External reference
Teprotumumab for the treatment of active thyroid eye disease
10.1056/nejmoa1910434 · 2020 · External reference
Treatment of hyperthyroidism in Graves' disease complicated by thyroid eye disease
10.1210/clinem/dgaf009 · 2025 · External reference
Novel inflammatory biomarkers in thyroid eye disease
10.1530/eje-22-0247 · 2022 · External reference
Molecular biomarkers in thyroid eye disease: A literature review
10.1097/iop.0000000000002466 · 2023 · External reference
BPIFA1 is a secreted biomarker of differentiating human airway epithelium
10.3389/fcimb.2022.1035566 · 2022 · External reference
PDGFRα(+)DPP4(+) fibroblasts-macrophage crosstalk induces orbital fibrosis in treatment-resistant thyroid eye disease via the GAS6-AXL pathway
10.1002/advs.202511404 · 2025 · External reference
Modulation of intestinal signal transduction pathways: Implications on gut health and disease
10.1016/j.ejphar.2025.177531 · 2025 · External reference
Macrophage M1/M2 polarization
10.1016/j.ejphar.2020.173090 · 2020 · External reference
Mitochondrial dysfunction prevents repolarization of inflammatory macrophages
10.1016/j.celrep.2016.09.008 · 2016 · External reference
Molecular biomarkers of Graves' ophthalmopathy
10.1016/j.yexmp.2018.11.004 · 2019 · External reference
Phasing and continuity of the treatment of thyroid eye disease in patients with Graves' disease
10.14341/probl13307 · 2023 · External reference
Disrupting calcium homeostasis and glycometabolism in engineered lipid-based pharmaceuticals propel cancer immunogenic death
10.1016/j.apsb.2024.12.018 · 2025 · External reference
Future projections in thyroid eye disease
10.1210/clinem/dgac252 · 2022 · External reference
